Boerner expects room for multiple agents in small cell lung cancer as patients are further subtyped.
what is likely to occur is you are going to see patients continue to be subtype. And additional therapies be required to treat patients not only in initial lines of therapy, but subsequent lines of therapy and I think at the end of the day, there is gonna be room for multiple agents to, be engaged to help treat these patients.
All statements by Chris Boerner ›
Boerner says BMS now has eight growth-portfolio drugs each annualizing over $1B, giving a broad growth base.
We now have 8 growth portfolio medicines, each annualizing over $1 billion based on Q3 sales, giving us a broad base of growth drivers.
Boerner says positive Phase 3 data strengthen conviction in CELMoDs and the protein degradation platform, where BMS leads.
These results further strengthen our conviction in CELMoDs and our broader targeted protein degradation platform, where BMS is a clear leader.
Boerner says BMS is embedding AI across its entire value chain, from discovery to manufacturing.
AI, as we have said on previous calls, is an important area and investment for us We are focused really on thinking about how we can embed AI where it makes sense across the entire value chain of the company, everything from early stage discovery through commercialization, manufacturing, and virtually all of our enabling functions.
Boerner reaffirms business development as a top capital allocation priority while seeking external innovation.
BD continues, as we have said, consistently to be a top allocation priority. We have got a very strong late stage pipeline. But we are always gonna be looking for opportunities to source innovation externally if it makes sense for us to do so.
Boerner says Zolacel shows potentially transformational activity in autoimmune disease and BMS will continue the program despite the pause.
what I will tell you with Zolacel specifically is we are seeing potentially transformational activity We are excited to continue this program.